November 6, 2018 Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

November 2, 2018 Aclaris Therapeutics to Attend Upcoming Investor Conferences

October 29, 2018 Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018

October 22, 2018 Aclaris Announces Closing of Public Offering of Common Stock

October 17, 2018 Aclaris Announces Pricing of Public Offering of Common Stock

October 17, 2018 Aclaris Announces Proposed Public Offering of Common Stock

October 15, 2018 Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan

October 3, 2018 Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference

October 2, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 1, 2018 Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA® (hydrogen peroxide) Topical Solution 40%, (w/w)

October 1, 2018 Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups

September 24, 2018 Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts

September 21, 2018 Aclaris Therapeutics to Attend Upcoming Investor Conferences

September 17, 2018 Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting

September 5, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 21, 2018 Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research

August 3, 2018 Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

August 2, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 26, 2018 Aclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018

July 9, 2018 FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata

July 3, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 28, 2018 Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata

June 26, 2018 Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

June 15, 2018 Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer

June 12, 2018 Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses

June 4, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 30, 2018 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA

May 16, 2018 Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting

May 15, 2018 Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

May 11, 2018 Aclaris Therapeutics to Present at the 2018 American Hair Research Summit

May 10, 2018 Aclaris Therapeutics to Attend Upcoming Investor Conferences

May 8, 2018 Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

May 7, 2018 Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

May 2, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 24, 2018 Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018

April 24, 2018 Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee

April 23, 2018 Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia

April 6, 2018 Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada

April 3, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 29, 2018 Topical Solution May Be Less Toxic Option for Patients with Noncancerous Skin Growth

March 20, 2018 Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine

March 19, 2018 Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts

March 12, 2018 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments

March 9, 2018 Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders

March 6, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 28, 2018 Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018

February 8, 2018 Aclaris Therapeutics to Present Data on ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting

February 5, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 2, 2018 Aclaris Therapeutics to Attend Upcoming Investor Conferences

January 8, 2018 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts

January 4, 2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)